Comparative Pharmacology
Head-to-head clinical analysis: DEFLAZACORT versus ENTOCORT EC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFLAZACORT versus ENTOCORT EC.
DEFLAZACORT vs ENTOCORT EC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory effects via inhibition of inflammatory mediators such as cytokines and prostaglandins.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
9 mg orally once daily in the morning for up to 8 weeks.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Terminal elimination half-life is approximately 2-3 hours; clinically, the extended intestinal release formulation maintains local activity despite short systemic half-life.
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Primarily fecal (60-70%) with minimal renal excretion (<10%); extensively metabolized hepatically, metabolites excreted in bile and feces.
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."